Dual PI3K/mTOR Inhibitor BEZ235 combined with BMS-1166 Promoting Apoptosis in Colorectal Cancer
Authors:
Open Access
- 1 January 2024
- journal article
- research article
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 21 (10) , 1814-1823
Abstract
Background: BMS-1166, a PD-1/PD-L1 inhibitor, inhibits the binding of PD-L1 to PD-1, restores T cell function, and enhances tumor immune response. However, mutations in the tumor suppressor or impaired cellular signaling pathways may also lead to cellular transformation. In this study, the SW480 and SW480R cell lines were used as the model to elucidate the treatment with BMS-1166, BEZ235, and their combination.Keywords
This publication has 29 references indexed in Scilit:
- Flurbiprofen as a biphenyl scaffold for the design of small molecules binding to PD-L1 protein dimerBiochemical Pharmacology, 2020
- PHLDA2 regulates EMT and autophagy in colorectal cancer via the PI3K/AKT signaling pathwayAging, 2020
- NVP-BEZ235 inhibits thyroid cancer growth by p53- dependent/independent p21 upregulationInternational Journal of Biological Sciences, 2020
- Development of the Inhibitors That Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and MacrocyclesMolecules, 2019
- Establishment and Characterization of 5-Fluorouracil-Resistant Human Colorectal Cancer Stem-Like Cells: Tumor Dynamics under Selection PressureInternational Journal of Molecular Sciences, 2019
- PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerationsHuman Vaccines & Immunotherapeutics, 2019
- BEZ235 enhances chemosensitivity of paclitaxel in hepatocellular carcinoma through inhibiting the PI3K/Akt/mTOR pathway2019
- BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway2019
- Drug resistance and new therapies in colorectal cancerWorld Journal of Gastroenterology, 2018
- Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1Oncology Reports, 2018